Eos SENOLYTIX
Houston, US · Founded 2024 · Delaware corporation · 1 known investors
Eos SENOLYTIX develops senolytic peptides designed to restore cellular balance in aged or senescent cells across body organs, focusing on gerotherapeutics. The company targets age-related conditions through proprietary approaches to cellular rejuvenation.
Founders & leadership
Eos SENOLYTIX was founded in 2024 by Kevin Slawin, M.D..
KS
Kevin Slawin, M.D.Founder and CEO
KM
Board
JW
Jerold WinogradBoard director
FB
Frank Bartlett McGuyerBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$750K disclosed across 1 round · 2026
▶$750KraisedAug 2026 · 2 investors · PharmaceuticalsRule 506(b)
▶$750KraisedAug 2026 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kevin Mark SlawinExecutive Officer, Director
- Frank Bartlett McGuyerDirector
- Jerold WinogradDirector
- Offering amount
- $25M
- Amount sold
- $750K
- Minimum investment
- $250K
- Sales commissions
- $1.4M
- Placement agents
- Floww Private Markets US Inc., Floww Private Markets US Inc., Floww Private Markets US Inc.
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapPhoenix SENOLYTIX4 shared keywordsPhoenix SENOLYTIX develops gene therapies targeting senescent cells to address aging-related conditions. The company utilizes its ApoptiCIDe-CE™ platform technology, validated in human patients, to eliminate unwanted cells in the body.
Cenegenics3 shared keywordsCenegenics is a physician-led age management and performance health system that uses diagnostics and data-driven interventions to help individuals optimize strength, cognition, metabolic health, and longevity. The company serves individuals seeking personalized, medically grounded approaches to extending peak physical and cognitive performance.
Companies competing with Eos SENOLYTIX for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Pulmatrix to Merge With Eos SENOLYTIX, Rebrand on Nasdaq - TipRanks.comtipranks.com · Mar 2026Frequently asked questions
- What does Eos SENOLYTIX do?
- Eos SENOLYTIX develops senolytic peptides designed to restore cellular balance in aged or senescent cells across body organs, focusing on gerotherapeutics. The company targets age-related conditions through proprietary approaches to cellular rejuvenation.
- Who founded Eos SENOLYTIX?
- Eos SENOLYTIX was founded by Kevin Slawin, M.D. in 2024.
- Who are Eos SENOLYTIX's investors?
- Eos SENOLYTIX's investors include Rapha Capital Management, LLC.
- How much funding has Eos SENOLYTIX raised?
- Eos SENOLYTIX has disclosed $750K raised across 1 round.
- Where is Eos SENOLYTIX headquartered?
- Eos SENOLYTIX is headquartered in Houston, US.